.png){kind=icon}
.png){kind=icon}
Return
Targeted Therapy for Rare BRAF-Mutated Melanoma: Updated Multicenter Analysis and Launch of a Publicly Accessible Online Outcome Database
.png){kind=icon}
PRE
AI
DOI：10.1016/j.ejca.2025.115703.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Results confirm benefit of BRAFi/MEKi combinations in patients harboring rare BRAF mutations • Patients with BRAF class II and III mutations benefitted • ORR was higher in V600-nonE/K (45%) than non-V600 melanomas (26%). • A publicly accessible global database was developed to support clinical decision-making
Keywords:
BRAF mutations
BRAFi/MEKi combinations
ORR
V600-nonE/K
global database
Journal
IF:
7.1
Papers:
2.6W
Citations:
3.8W
Organization
View more organizations